

# The European perspective at the EAU-RF

Prof Anders Bjartell, MD PhD FEBU

Dept of Urology, Skåne University Hospital Malmö,  
Lund University, Sweden

Chairman EAU Research Foundation

Board member EAU Guidelines Office

25 November 2022 SAN  
RAFFAELE UROLOGIC  
ONCOLOGY RETREAT

# Disclosures/Conflict of Interest

Scientific Advisory Board and/or speaker honoraria

Accord, Astellas, AstraZeneca, Bayer, Ferring, IPSEN, Janssen, MSD, Sandoz

Research grants

Astellas, Bayer, Ferring

Co-founder

Glactone Pharma AB

Board Member

Glactone Pharma AB, Noviga AB

Shareholder


LIDDS AB, Glactone Pharma AB, WntResearch AB,

# Agenda

- EAU Research Foundation
- Previous and ongoing studies/registries
- Future strategies
  - Big Data, AI and Data Haven

# EAU Foundation for Urological Research

The mission of the EAU Research Foundation (EAU RF) is to promote, facilitate and stimulate clinical and basic research in European urology. We set out to achieve this mission by acting as a bridge between urological centres, research organisations and the EAU.



Development of a European network of urological research centres

# EAU Research Foundation Board



**Chairman**

A.S. Bjartell  
Malmö (SE)



**Director EAU Central  
Research Office**

W.P.J. Witjes  
Arnhem (NL)

## Clinical Studies



C Moore  
London (UK)



A. Necchi  
Milan (IT)



L. Kiemeny  
Nijmegen (NL)



S. Shariat  
Vienna (AT)

## EAU Registries

## Basic Research



G. Jenster  
Rotterdam (NL)

## Ex-Officio



**EAU**  
A. Stenzl  
Tübingen (DE)



**EUSP**  
Axel Merseburger  
Lübeck (DE)



**YAU**  
G. Cacciamani  
Los Angeles (US)

## Previous studies



### *The* NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

MAY 10, 2018

VOL. 378 NO. 19

#### MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis


V. Kasivisvanathan, A.S. Rannikko, M. Borghi, V. Panebianco, L.A. Mynderse, M.H. Vaarala, A. Briganti, L. Budäus, G. Hellawell, R.G. Hindley, M.J. Roobol, S. Eggener, M. Ghei, A. Villers, F. Bladou, G.M. Villeirs, J. Viridi, S. Boxler, G. Robert, P.B. Singh, W. Venderink, B.A. Hadaschik, A. Ruffion, J.C. Hu, D. Margolis, S. Crouzet, L. Klotz, S.S. Taneja, P. Pinto, I. Gill, C. Allen, F. Giganti, A. Freeman, S. Morris, S. Punwani, N.R. Williams, C. Brew-Graves, J. Deeks, Y. Takwoingi, M. Emberton, and C.M. Moore, for the PRECISION Study Group Collaborators\*

The use of risk assessment with MRI before biopsy and MRI-targeted biopsy was superior to standard transrectal ultrasonography–guided biopsy in men at clinical risk for prostate cancer who had not undergone biopsy previously.

# Previous studies



2013 – 2019 **STOPPED** for safety reason after 359 pts:



## Conclusions:

The reduced frequency schedule was inferior to the standard schedule regarding the time to first recurrence.


Further recruitment of patients was stopped immediately to avoid harm in the reduced frequency BCG arm.





# Study design

## Open-label Phase 2. High-risk UTCa








**Primary Objective:** Evaluate relapse-free survival

**Secondary Objectives:** Evaluate safety, tolerability and overall survival

Study restricted to Italy but now **stopped**. **Only** 5/43 pat pos genetic FGFR3 test (>10%)



# Ongoing projects (still recruiting)

|                |  |                         |   |
|----------------|--|-------------------------|---|
| VENUS study    |  | Female incontinence     | ▼ |
| PHOENIX study  |  | Penile implants         | ▼ |
| PRIME study    |  | bpMRI                   | ▼ |
| EASE RCC study |  | RCC active surveillance | ▼ |
| MARS study     |  | Priapism                | ▼ |
| ROGUE-1 study  |  | T1BCa registry          | ▼ |



Recruitment continues for female artificial urinary sphincter registry (VENUS)

Mon, 27 Jun 2022

Female Urology

EAU Research Foundation EAU RF

Research

Incontinence




EAU RF PHOENIX: Recruitment started

Fri, 13 May 2022

Andrology

Research


EAU Research Foundation EAU RF



ROGUE-1: Multicentric, prospective T1 BCa registry

Fri, 29 Oct 2021

Bladder Cancer



**PRIME:** 500-patient prospective, international, within-patient, multicentre, level 1-evidence

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



Platinum Opinion

**Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?**

Alexander Ng<sup>a,b</sup>, Pramit Khetrapal<sup>c,d</sup>, Veeru Kasivisvanathan<sup>b,c,\*</sup>

\*UCL Medical School, University College London, London, UK; <sup>b</sup>BURST Research Collaborative, London, UK; <sup>c</sup>Division of Surgery and Interventional Science, University College London, London, UK; <sup>d</sup>Department of Urology, Whipps Cross Hospital, Barts Health NHS Trust, London, UK



Prof Caroline Moore



Dr Veeru Kasivisvanathan

**University College London Hospital, UK**

**AIM:** To assess whether bpMRI is non-inferior to mpMRI in detecting csPCa

FIRST 200 DAYS

9

SITES OPENED

142


PATIENTS RECRUITED

# Upcoming studies/registries



**BladdeR Variants RegistrY**  
**Rare Bladder cancer variants.**

PI Andrea Necchi.  
PM Fillipo Pedersoli



**A prospective multicentre registry for patients  
undergoing focal therapy for localised prostate cancer.**

**PI:**  
**Eric Barret Paris**  
**Juan I. Martinez-Salamanca, Madrid**

## ***OLIGOMET: Outcomes of local treatment for oligometastatic prostate cancer diagnosed using PSMA-PET***

Principal investigators:

Prof. Shahrokh Shariat, Dr. Pawel Rajwa,

Department of Urology, Medical University of Vienna, Vienna, Austria

Dr. Giorgio Gandaglia, Prof. Alberto Briganti

Department of Urology, Ospedale San Raffaele IRCCS, Milan, Italy

|                            |   |
|----------------------------|---|
| <b>Study Phase</b>         | <b>Prospective</b>  |
| <b>Objectives</b>          | <b>Primary:</b><br>To analyze the time to castration-resistant prostate cancer (CRPC) in patients treated with local therapy for oligometastatic prostate cancer diagnosed using PSMA-PET imaging |
| <b>Study Design</b>        | Prospective, multicenter, observational study   |
| <b>Number of centers</b>   | 12  |
| <b>Planned Sample Size</b> | Approximately 250 patients  |
| <b>Planned start date</b>  | May 1 <sup>st</sup> 2023  |





Next generation urology patient care  
is evidence based, patient focussed,  
cost effective and data-driven

## PIONEER & the BD4BO mission



Prof James N'Dow

- **PIONEER** is part of the Innovative Medicine Initiative's (IMI's) "Big Data for Better Outcomes" (BD4BO) programme
- The **BD4BO mission** is to improve health outcomes and healthcare systems in Europe by maximising the potential of Big Data



2017 - 2023



# PIONEER consortium

PIONEER is:

- A network of **35 public and private stakeholders**
- who collaborate closely with internal and external **data providers**
- to build a prostate cancer **Big Data & analytics platform.**








# BIG DATA PLATFORM

## THE EUROPEAN NETWORK OF EXCELLENCE FOR BIG DATA IN PROSTATE CANCER

Together we can ensure each individual patient receives the right treatment for them at the right time.




# PIONEER Data sources and access overview




## Dataset onboarding to the PIONEER Platform

(number of prostate cancer patients per dataset shown)



# PIONEER Big Data Platform



- PIONEER Big Data platform at CASUS / HZDR launched and active
- Federated & centralised model
- Integrated analytics applications


# OPTIMA – PCa, lung & breast cancer



## What we want to achieve

Two pillars form the foundation of OPTIMA-AI: Clinical decision support based on computer-interpretable guidelines and AI-discovery of new knowledge from real-world data

2021 - 2026



## A strong alliance of public & private partners

38 Partners across 9 countries in the following fields:

- IMI experienced researchers / SMEs
- Professional medical societies
- Cancer key opinion leaders
- Leading guideline developers
- Patient organisations
- Committed industry partners
- EMA steering group members
- AI in healthcare experts
- Implementation scientists









































More info: [www.prostate-pioneer.eu](http://www.prostate-pioneer.eu)





# Transforming urology care






## Why focus on Real World Data (RWD) ?

- Evidence gaps not filled fast enough with high quality RCTs
- Mistake to think published outcomes from Centres of Excellence representative of practice in general
- Evidencing the purpose of EAU demands collecting RWD systematically



Evidence Based Medicine is evolving  
to include Real World Evidence (RWE)





# FUTURE AIMS

Expand the portfolio of investigator-initiated **clinical research projects and registries** through seeding grants and other set-ups

Supporting Young Academic Urologists (EAU - YAU)

Consensus meetings and broad collaborations to **fill gaps of knowledge**

Focus on Big Data, **Real-World Data, Data Haven**

<https://uroweb.org/offices/eau-foundation-for-urological-research>

